An Australian study found a self-reported life-time treatment uptake of 10% and an increasing trend in the annual treatment uptake (0.5% in 1999–2% in 2011) among HCV antibody-positive PWID [19] .
← all excerpts
Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.
1
—
—